FY25 consensus $2.06B. Narrows FY25 adjusted EBITDA view to $140M-$165M from $135M-$165M.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target raised to $16 from $14 at Truist
- Evolent Health’s Positive Outlook: Strong Q2 Performance and Promising Pipeline Growth Justify Buy Rating
- Evolent Health appoints Lim as chief clinical officer, Way as CFO
- Evolent Health news Friday ‘incrementally positive,’ says UBS
- GMS jumps after report of competing suitors, Couchbase gets bought: Morning Buzz